Champions Oncology Inc (CSBR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $65.49M
Last updated: Nov 17, 2026 at 10:50 AM ET
Champions Oncology Inc (CSBR) Valuation Multiples
Champions Oncology (CSBR) trades at 1.0x sales and 16.3x book value. Its P/S of 1.0x is below its 5-year median of 1.6x. Its forward P/E is 22.9x.
Current Multiples
Its enterprise value is 133.8x its EBITDA.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 22.9x |
| Price to sales | 1.0x |
| Price to book | 16.3x |
| EV/EBITDA | 133.8x |
| PEG | N/A |
| FCF yield | -9.7% |
Historical Medians
Against its 10-year medians, its P/S is 54.5% below 2.2x and its P/B is 28.2% below 22.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.0x | 1.6x | 2.2x |
| P/B | 16.3x | 19.1x | 22.7x |
Valuation History
Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 20.3x in 2025 to 857.0x in 2024. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $6.91 | 20.3x | 1.6x | 22.9x |
| 2024 | $8.57 | 857.0x | 2.2x | 171.1x |
| 2023 | $5.62 | N/A | 1.5x | 815.6x |
| 2022 | $4.51 | 112.8x | 1.1x | 6.7x |
| 2021 | $8.36 | 119.4x | 2.5x | 13.9x |
| 2020 | $10.79 | N/A | 3.6x | 20.5x |
| 2019 | $8.33 | N/A | 3.4x | 45.8x |
| 2018 | $7.81 | 260.3x | 3.8x | 44.2x |
| 2017 | $3.88 | N/A | 2.4x | 114.3x |
| 2016 | $2.53 | N/A | 1.8x | 8.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CSBR
What is CSBR's forward P/E ratio?
Champions Oncology has a forward P/E ratio of 22.9x.
Is CSBR stock overvalued?
GNG's valuation label for CSBR is Undervalued.
What is CSBR's price to sales ratio?
Champions Oncology has a price to sales ratio of 1.0x.
CSBR pages: Overview, Earnings, Financials, Valuation, Competitors